[Featured Stock] Hanmi Pharm Gains Over 5% on Strong New Drug Sales and Contract Manufacturing Prospects...

Hanmi Pharm's stock price is showing strength in the early trading session on the 6th. This is interpreted as being driven by securities analysts' assessments that major new drug sales are better than expected and there is a possibility of contract manufacturing for a popular obesity treatment.

As of 9:32 a.m. on the same day in the KOSPI market, Hanmi Pharm is trading at 320,500 KRW, up 5.60% from the previous trading day.

The stock price also rose as much as 6.59% to 323,500 KRW shortly after the market opened compared to the previous day.

[Image source=Yonhap News]

On this day, Hi Investment & Securities raised Hanmi Pharm's target price from 380,000 KRW to 390,000 KRW.

Researcher Lee Ho-cheol of Hi Investment & Securities analyzed, "The obesity treatment 'Wegovy' has become an obesity injection that is in such high demand that it cannot be sold enough due to a steep increase in demand while production facilities are insufficient."

Wegovy is an obesity treatment from the Danish pharmaceutical company Novo Nordisk, and it is a GLP-1 agonist hormone that induces a feeling of fullness.

Researcher Lee said, "Considering the current supply shortage issue of GLP-1 agonists and the characteristics of the manufacturing process, contract manufacturing orders from Hanmi Pharm, which has microbial-based production facilities, are expected," adding, "If GLP-1 agonist contract manufacturing orders are secured, a corporate value increase of 1.656 trillion KRW is anticipated."

He also said, "Sales of 'Rolvadon,' one of Hanmi Pharm's major new drugs, exceeded expectations," raising the new drug's value from the previous 269 billion KRW to 285 billion KRW.

This content was produced with the assistance of AI translation services.